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Abstract
Islet transplantation provides a ‘‘cure’’ for type 1 diabetes but is limited in part by recurrent autoimmunity mediated by
b cell-specific CD4+ and CD8+ T cells. Insight into the T cell receptor (TCR) repertoire of effector T cells driving recurrent
autoimmunity would aid the development of immunotherapies to prevent islet graft rejection. Accordingly, we used a multi-
parameter flow cytometry strategy to assess the TCR variable b (Vb) chain repertoires of T cell subsets involved in
autoimmune-mediated rejection of islet grafts in diabetic NOD mouse recipients. Naı̈ve CD4+ and CD8+ T cells exhibited
a diverse TCR repertoire, which was similar in all tissues examined in NOD recipients including the pancreas and islet grafts.
On the other hand, the effector/memory CD8+ T cell repertoire in the islet graft was dominated by one to four TCR Vb
chains, and specific TCR Vb chain usage varied from recipient to recipient. Similarly, islet graft- infiltrating effector/memory
CD4+ T cells expressed a limited number of prevalent TCR Vb chains, although generally TCR repertoire diversity was
increased compared to effector/memory CD8+ T cells. Strikingly, the majority of NOD recipients showed an increase in TCR
Vb12-bearing effector/memory CD4+ T cells in the islet graft, most of which were proliferating, indicating clonal expansion.
Importantly, TCR Vb usage by effector/memory CD4+ and CD8+ T cells infiltrating the islet graft exhibited greater similarity
to the repertoire found in the pancreas as opposed to the draining renal lymph node, pancreatic lymph node, or spleen.
Together these results demonstrate that effector/memory CD4+ and CD8+ T cells mediating autoimmune rejection of islet
grafts are characterized by restricted TCR Vb chain usage, and are similar to T cells that drive destruction of the endogenous
islets.
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Introduction
Type 1 diabetes (T1D) is characterized by the autoimmune
destruction of the insulin-secreting b cells residing in the
pancreatic islets of Langerhan’s [1–5]. In humans and the NOD
mouse, a spontaneous model for T1D, b cell autoimmunity is
viewed as a chronic inflammatory response mediated by auto-
reactive CD4+ and CD8+ T cells [6–10]. Initiation of the
diabetogenic response involves T cell recognition of a limited
number of b cell autoantigens. As b cell autoimmunity progresses,
several autoantigens are targeted due to intra- and inter-molecular
epitope spread, resulting in the expansion of multiple clonotypes of
pathogenic b cell-specific effector T cells (Teff) [11–18]. The latter
is evident by a T cell receptor (TCR) repertoire marked by
expression of multiple TCR variable (V) genes by islet resident T
cells [19–21], and b cell-specific T cell clones [19,22–26]. Once
,80% of the b cell mass has been destroyed and/or rendered
nonfunctional, hyperglycemic blood levels are achieved and the
onset of overt diabetes diagnosed.
Islet transplantation is one approach to replace b cells and
restore euglycemia in T1D patients [27–29]. Short-term efficacy
has been obtained in chronic T1D patients receiving an islet
transplant and immunosuppressive drugs. However, widespread
application of islet transplantation is limited by a variety of factors,
including the persistence of autoreactive T cells which destroy the
grafted b cells [6,9,10,30,31]. A better understanding of the nature
of the pathogenic b cell-specific T cells and the response associated
with recurrent autoimmunity is critical for the development of
immunotherapies that promote long-term islet graft-specific
tolerance. Currently, it is unclear whether the same clonotypes
of b cell-specific CD4+ and CD8+ Teff drive destruction of both
endogenous and grafted b cells. Our earlier work analyzing TCR
Va and Vb gene usage by Major Histocompatibility Complex
(MHC) class I tetramer-sorted CD8+ T cells specific for islet-
specific glucose-6-phosphatase catalytic subunit-related protein
derived peptide (IGRP206–214) indicated that islet graft destruction
was mediated by clonotypes also prevalent in the pancreas of the
diabetic NOD recipients [32]. However, whether this is a general
observation for all b cell-specific CD8+ Teff has yet to be
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established. Furthermore, the clonotypic composition of b cell-
specific CD4+ Teff mediating islet graft destruction has not been
defined. Due to the several known and potential unknown
autoantigens driving T1D, analysis of b cell-specific T cell
populations by tetramer analysis is cumbersome and impractical
to address these key issues.
Accordingly, we have employed a novel multi-parameter flow
cytometry approach to determine the TCR Vb usage by CD4+
and CD8+ T cells infiltrating grafted and endogenous islets in
individual diabetic NOD mice. The approach is advantageous
since TCR Vb usage can be readily assessed for different subsets of
CD4+ and CD8+ T cells residing in multiple tissues of an
individual animal. Herein we show that both CD4+ and CD8+
effector/memory T cells (Teff/mem) infiltrating an islet graft and
the pancreas exhibit restricted TCR Vb usage. Notably, whereas
TCR Vb usage by islet graft-infiltrating CD8+ Teff/mem is highly
variable among individual animals, TCR Vb12 is preferentially
expressed by CD4+ Teff/mem in the majority of NOD recipients.
Importantly, TCR Vb usage by CD4+ and CD8+ Teff/mem is
most similar between grafted and endogenous islets compared to
peripheral lymphoid tissues in an individual NOD recipient. These
results suggest that immunodominant b cell-specific T cells
attacking the endogenous pancreas also mediate islet graft
destruction.
Results
Defining TCR Vb Repertoire Usage by Multi-parameter
Flow Cytometry
A modified multi-parameter flow cytometry method was used to
identify single TCR Vb populations using combinations of
fluorochrome- and biotinylated-labeled antibodies specific for
TCR Vb chains in individual diabetic NOD mice receiving
syngeneic islet grafts [33–36]. Three different staining panels were
designed in which up to 6 different TCR Vb chains could be
detected simultaneously for a given staining set (Figure 1A).
Typically, a small non-reactive population, defined as T cells
expressing TCR Vb chains for which antibodies are unavailable,
was also present. In general $75% of all CD4+ and CD8+ T cells
stained with the anti-Vb antibody panel used (Tables 1,2,3,4).
CD4+ and CD8+ T cells were co-stained with antibodies specific
for CD90.2 (Thy1.2), CD44 and CD62L to identify eff/mem
(CD44hi CD62Llo) and naı̈ve (CD62Lhi CD44lo) T cell subsets
[37–39]. The majority of T cells exhibited one of these two
phenotypes (Figure 1B). Although CD44 did not permit distinction
between Teff and Tmem, activated and naı̈ve T cells were readily
discerned. Foxp3-expressing immunoregulatory T cells (Treg)
were also distinguished from naı̈ve and eff/mem CD4+ T cells in
the analyses by intracellular staining of Foxp3 (Figure 1B).
Diabetic NOD female mice (blood glucose levels .250 mg/dL)
were implanted with 500 syngeneic NOD.scid islets under the
kidney capsule. Ten days post-implantation, a time at which
recurrent diabetes is first detected, TCR Vb usage by CD4+ and
CD8+ naı̈ve and Teff/mem was examined in the islet graft, the
renal lymph node (RLN) draining the graft site, pancreas,
pancreatic lymph node (PLN), and spleen of individual recipients.
Naive T cells Infiltrating Grafted and Endogenous Islets
Exhibit TCR Vb Chain Usage Similar to Naı̈ve T cells in
Lymphoid Tissues
TCR Vb usage by naı̈ve splenic CD8+ and CD4+ T cells, which
represents the T cell repertoire under homeostasis, was essentially
identical among the NOD recipients, and similar to the PLN and
RLN (Figure 2). Interestingly, naı̈ve CD8+ (Figure 2A) and CD4+
(Figure 2B) T cells found in the islet grafts and pancreas also
exhibited a TCR Vb repertoire analogous to the spleen. Naı̈ve T
cells were found at a relatively high frequency in the grafted
(CD4+: 35.066.3%; CD8+: 25.766.3%) and endogenous (CD4+:
52.863.2%; CD8+: 40.364.0%) islets. These results demonstrate
that TCR Vb usage by naı̈ve CD4+ and CD8+ T cells is diverse,
with minimal (if any) variability among the tissues including
grafted and endogenous islets in a given animal, and among NOD
recipients.
Islet Graft-infiltrating CD8+ Teff/mem Exhibit Restricted
TCR Vb Chain Usage
In contrast to naı̈ve CD8+ T cells, skewed TCR Vb usage by
CD8+ Teff/mem was observed in both the islet graft and pancreas
of NOD recipients (Figure 3A; Tables 1, 2). Islet graft-infiltrating
CD8+ Teff/mem preferentially expressed 1 to 4 TCR Vb chains,
making up.50% of the TCR Vb repertoire in some mice (e.g.
mouse #1, 2, 9, 11) (Table 1). Furthermore, TCR Vb usage varied
in the islet grafts among individual recipients which was readily
evident: 1) by marked changes in the frequency of the majority of
Vb families (Figure 3A) compared to naı̈ve CD8+ T cells found in
the spleen or islet graft (Figure 2A), and 2) when TCR Vb usage by
CD8+ Teff/mem was normalized to splenic naı̈ve CD8+ T cells
(Figure 3B). Generally, the dominant TCR Vb chains expressed
by CD8+ Teff/mem infiltrating the graft were also prominent in
the pancreas. For example, in mouse #2 the TCR Vb repertoire
of islet graft CD8+ Teff/mem was dominated by TCR Vb4
(21.8%), Vb5.1/2 (19.5%), Vb2 (10.9%), and Vb8.1/2 (10.3%)
(Table 1); in the endogenous islets TCR Vb4 (24.4%), Vb5.1/2
(13.9%), and Vb8.1/8.2 (13.9%) were also prevalent, although
expression of TCR Vb2 (2.1%) was limited (Table 2). These
findings indicate that TCR Vb usage by CD8+ Teff/mem is
restricted in both the grafted and endogenous islets, and is variable
among individual recipients.
Islet Graft-infiltrating, TCR Vb8.1/2-expressing CD8+ Teff/
mem exhibit IGRP206–214-specificity
The frequency of TCR Vb8.1/2 expressing CD8+ Teff/mem
infiltrating the grafted and endogenous islets was increased
compared to splenic naı̈ve CD8+ T cells in the majority (7/13)
of NOD recipients (Figure 3B). We and others have shown that
IGRP206–214-specific CD8
+ T cells preferentially express TCR
Vb8.1/2, and are a dominant clonotype mediating b cell de-
struction in NOD mice [32]. Accordingly, the frequency of
IGRP206–214-specific CD8
+ T cells among TCR Vb8.1/2-expres-
sing CD8+ Teff/mem in the islet grafts (and pancreas) was
determined using H2Kd-IGRP tetramers. Strikingly, up to 65% of
TCR Vb8.1/2-expressing CD8+ Teff/mem in the grafted islets
stained with the H2Kd-IGRP (Figure 4). Interestingly, within
a given recipient similar frequencies of IGRP206–214-specific CD8
+
Teff/mem were detected in the grafted and endogenous islets
(Figure 4). The increase in IGRP206–214-specific CD8
+ Teff/mem
within the pool of TCR Vb8.1/2 expressing CD8+ Teff/mem was
tissue-specific since H2Kd-IGRP-binding TCR Vb8.1/2-expres-
sing CD8+ Teff/mem in the spleen was ,0.05%. These results
demonstrate that IGRP206–214-specific CD8
+ Teff/mem make up
a significant portion of the TCR Vb8.1/2-expressing CD8+ Teff/
mem that infiltrate both the grafted and endogenous islets.
TCR Vb12 Usage is Increased by Islet Graft-infiltrating
CD4+ Teff/mem
Islet graft-infiltrating CD4+ Teff/mem were characterized by 1
to 4 prevalent TCR Vb chains (Figure 5A; Table 3), similar to
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Figure 1. Multiple TCRs can be examined in a pool of T cells. (A) TCR Vb usage was determined with 3 different stain sets (A, B and C) (see
Materials and Methods). Three colors were used – FITC, PE, and streptavidin Alexa594, to visualize up to 6 different TCR Vb chains per sample. (B)
Representative gating scheme in which splenic CD4+ and CD8+ T cells (CD90.2+) were divided into naı̈ve (CD62LhiCD44lo) and Teff/mem
(CD62LloCD44hi) subsets. CD4+ T cells were further defined based on FoxP3-expression.
doi:10.1371/journal.pone.0052054.g001
Figure 2. Analyses of TCR Vb chain usage by naı̈ve CD4+ and CD8+ T cells in islet graft NOD recipients. Frequency of TCR Vb chains
expressed by naı̈ve CD8+ (A) and CD4+ (B) T cells in the spleen, PLN, RLN, pancreas, and islet graft of individual NOD recipients (n = 13).
doi:10.1371/journal.pone.0052054.g002
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Figure 3. Analyses of TCR Vb chain usage by CD8+ Teff/mem in islet graft NOD recipients. (A) Percentage of CD8+ Teff/mem expressing
specific TCR Vb chains in spleen, PLN, RLN, pancreas, and islet graft of individual NOD mice (n = 13). (B) The frequency of TCR Vb chain usage by CD8+
Teff/mem was normalized by subtracting the frequency of the corresponding TCR Vb chain expressed by splenic, naı̈ve CD8+ T cells for a given NOD
recipient.
doi:10.1371/journal.pone.0052054.g003
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CD8+ Teff/mem. However, unlike CD8+ Teff/mem, the TCR
Vb repertoire expressed by CD4+ Teff/mem in the grafts of most
NOD recipients (Figure 5A) generally resembled the diverse TCR
Vb profile used by naı̈ve CD4+ T cells in the spleen (Figure 2B).
The notable exception was TCR Vb12 expression by CD4+ Teff/
mem, which was increased in the islet grafts (and pancreas) of the
majority of NOD recipients compared to naı̈ve CD4+ T cells and
CD4+ Teff/mem in the spleen (Figures 2B, 5A; Tables 2, 3).
Skewing towards TCR Vb12 usage by CD4+ Teff/mem in the
islet graft and to a lesser degree in the pancreas was further evident
when TCR Vb usage within the respective tissues was normalized
to the TCR repertoire of splenic naı̈ve CD4+ T cells (Figure 5B).
Normalized TCR Vb12 usage by CD4+ Teff/mem was increased
in grafted (10.067.3%) and endogenous (3.963.3%) islets relative
to CD4+ Teff/mem found in the spleen (20.160.8), RLN
(2.061.6%) and/or PLN (20.360.6%) (Figures 5B, 6A). While
TCR Vb12 did not dominate the CD4+ Teff/mem repertoire in
all recipients, ranging between ,5 to 30% of the total CD4+ Teff/
mem population (Tables 3, 4), the largest percent increase was
nevertheless detected for TCR Vb12 in the islet graft and pancreas
of the majority of recipients (Figures 5B, 6A). In contrast, despite
being prevalent among all recipients, TCR Vb8.1/2 usage by
CD4+ Teff/mem in islet grafts and the pancreas was reduced
relative to the TCR repertoire of naı̈ve CD4+ T cells (Figure 5B).
The marked increase in islet graft-infiltrating TCR Vb12-
expressing CD4+ Teff/mem may be explained by tissue-specific




























2 1.8 10.9 2.8 1.6 1.3 5.3 0.3 0.2 6.0 6.3 19.0 2.0 11.3
3 0.1 0.2 0.4 0.2 3.5 0.4 0.2 0.2 0.0 0.0 0.1 0.3 0.0
4 3.1 21.8 2.3 0.7 0.5 2.2 5.6 1.1 2.1 5.9 3.5 3.8 0.7
5.1/2 5.6 19.5 8.9 1.1 2.6 1.5 2.4 3.4 1.7 3.9 2.0 5.3 2.8
6 7.9 6.0 20.7 11.1 11.2 4.5 3.5 5.0 10.6 8.3 4.2 8.4 12.1
7 0.8 1.3 1.1 3.9 3.0 1.4 4.3 1.8 0.6 3.6 5.8 1.7 1.5
8.1/2 28.6 10.3 22.6 15.5 7.8 27.7 32.3 29.4 16.8 12.7 36.6 14.6 21.9
8.3 2.9 2.5 3.2 1.9 7.2 2.5 5.1 4.7 1.3 4.7 3.2 4.7 4.9
9 0.7 0.6 1.5 0.9 0.7 8.7 1.7 0.7 0.6 2.2 0.7 1.9 0.8
10 29.3 1.5 5.9 3.9 6.1 4.1 5.1 1.0 26.3 3.9 2.0 8.5 1.4
11 2.3 1.0 3.3 1.1 4.5 3.3 3.3 6.5 1.6 8.7 2.1 11.7 1.8
12 0.6 1.0 1.7 0.9 5.1 0.4 1.1 0.4 0.2 1.3 0.3 2.2 2.4
13 3.2 1.6 4.3 26.1 2.5 0.9 3.0 2.6 1.0 2.6 15.0 3.6 6.9
14 0.7 1.5 3.5 0.3 2.5 2.6 3.3 2.1 1.4 1.4 3.1 1.3 0.8
Nonreactive 1.8 10.9 2.8 1.6 1.3 5.3 0.3 0.2 6.0 6.3 19.0 2.0 11.3
doi:10.1371/journal.pone.0052054.t001
Table 2. Frequency of TCR Vb chains expressed by pancreas infiltrating CD8+ Teff/mem.
Vb Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 Mouse 7 Mouse 8 Mouse 9 Mouse 10Mouse 11Mouse 12Mouse 13
2 1.5 2.7 2.4 2.4 0.6 5.6 1.4 0.2 8.1 2.6 13.9 0.7 4.8
3 0.0 2.1 0.0 6.0 2.8 0.6 0.4 0.1 0.1 0.1 0.0 0.1 0.0
4 1.5 24.4 6.8 0.8 0.6 2.4 2.2 1.9 2.5 8.9 4.1 1.3 0.4
5.1/2 5.5 13.9 5.8 0.9 2.7 3.4 3.7 3.5 3.1 1.7 2.9 3.1 2.0
6 19.0 6.1 16.8 5.5 10.3 6.1 6.1 5.0 7.2 3.1 3.5 7.4 11.4
7 3.0 1.6 0.8 4.0 2.5 3.2 5.4 2.2 1.5 6.0 3.8 1.7 1.4
8.1/2 24.7 13.9 17.0 15.8 8.5 24.6 31.7 26.6 22.4 30.8 28.2 13.7 14.8
8.3 5.3 5.9 3.8 3.1 5.3 3.3 7.7 2.3 2.4 2.5 3.4 3.1 3.6
9 0.8 1.3 0.9 0.8 1.6 8.5 1.9 0.3 0.6 1.0 0.6 3.2 0.0
10 9.0 4.6 7.8 1.5 8.8 2.2 4.6 1.6 7.2 4.1 3.0 5.1 0.5
11 4.8 2.0 6.1 0.6 3.9 4.9 6.7 7.3 1.6 4.1 5.3 10.4 2.9
12 0.4 0.7 1.5 0.8 5.5 1.8 1.5 1.7 0.3 1.7 0.3 2.1 2.9
13 2.8 2.6 8.6 50.4 2.4 2.0 4.9 3.0 2.7 0.5 9.7 3.3 6.8
14 1.0 1.4 2.7 0.5 3.4 2.1 2.4 2.7 3.7 1.9 6.9 1.2 0.8
Nonreactive 20.7 17.0 19.0 7.0 41.2 29.3 19.4 41.8 36.7 31.1 14.5 43.5 47.9
doi:10.1371/journal.pone.0052054.t002
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expansion. To address this possibility, the proliferative status of
TCR Vb12-expressing CD4+ Teff/mem was examined by
measuring Ki67 expression [40,41]. The majority (up to 88%) of
TCR Vb12-expressing CD4+ Teff/mem in islet grafts were Ki67+
(Figure 6B). The frequency of Ki67+ TCR Vb12-expressing CD4+
Teff/mem was significantly increased (,2.5-fold) in the islets, and
to a lesser extent in the pancreas, compared to the corresponding
splenic CD4+ Teff/mem (Figure 6B). Interestingly, the frequency
of Ki67+ TCR Vb12-expressing CD4+ Teff/mem was also
increased in the draining RLN compared to the spleen
(Figure 6B). These findings indicate that in most NOD recipients
the TCR Vb repertoire in islet grafts is characterized by an
increase in TCR Vb12 usage, which in turn is associated with
elevated Vb12-specific CD4+ Teff/mem proliferation.
CD8+ Teff/mem Exhibit Limited TCR Vb Chain Diversity in
Grafted and Endogenous Islets
To more accurately assess the level of diversity among TCR Vb
chains expressed by naı̈ve T cells and Teff/mem in the respective
tissues, the Shannon entropy was calculated. The Shannon
entropy within a given population represents both the species
richness (number of Vb chains expressed) and relative abundance
(proportion of each Vb chain) in the sample [42]. Hence, if a pool
of T cells expresses a small number TCR Vb chain families that
are prevalent, entropy will be correspondingly reduced relative to
a TCR repertoire consisting of several evenly distributed Vb chain
families. As expected, the entropy of naı̈ve CD4+ and CD8+ T cells
was nearly identical for all tissues (data not shown), indicating
a similar level of TCR Vb diversity. In contrast, the entropy for
TCR Vb chains of CD8+ Teff/mem was reduced in the pancreas,
and significantly lower in islet grafts compared to spleen, PLN and
RLN (Figure 7A), thereby indicating restricted TCR Vb usage.
On the other hand, entropy of TCR Vb chains expressed by
CD4+ Teff/mem in grafted and endogenous islets was similar to
that detected for spleen, PLN and RLN (Figure 7A). Furthermore,
entropy for islet graft-infiltrating CD4+ (2.2360.02) versus CD8+
(2.0360.02) Teff/mem was significantly increased (p = 0.03;
Mann-Whitney U). These data demonstrate that CD8+ Teff/
mem in the islet graft, and to a lesser extent the pancreas, have
significantly restricted TCR Vb chain usage in comparison to
CD8+ Teff/mem in spleen and lymph nodes. The TCR repertoire
of CD4+ Teff/mem in the grafted (and endogenous) islets,
however, is more diverse than that of CD8+ Teff/mem.
Similar TCR Vb Chain Repertoires are Expressed by Teff/
mem Infiltrating the Islet Graft and Pancreas
As noted earlier, TCR Vb usage by CD4+ and CD8+ Teff/mem
was similar between the islet graft and pancreas in individual
recipients (Figures 3, 5; Tables 1,2,3,4). The Kullback-Liebler
divergence was employed to quantify the level of similarity of TCR
Vb usage among CD4+ and CD8+ naı̈ve and Teff/mem in the
respective tissues. The Kullback-Liebler divergence is a measure of
the difference between two distributions, and as such allows for the
comparison of Vb usage similarities between tissues [43–45];
divergence is low for instance if two Vb distributions are similar.
TCR Vb usage among naı̈ve CD4+ and CD8+ T cells was similar
for the respective tissues, with a divergence index of approximately
0.0 (data not shown). Notably, the average divergence index
detected for CD8+ Teff/mem in the islet graft versus pancreas
(0.1160.05) was reduced relative to comparisons between the islet
graft and the spleen (0.1860.03), PLN (0.2260.03), and RLN
(0.2460.03) (Figure 7B). Similar trends were observed for islet
graft-infiltrating CD4+ Teff/mem where the divergence index for
the TCR repertoire between the islet graft and pancreas
(0.05960.02) was less than the divergence index calculated for
comparisons between the islet graft versus spleen (0.1460.03),
PLN (0.1560.03) and RLN (0.1360.03) (Figure 7B). These results
demonstrate that the distribution of Vb usage by CD4+ and CD8+
Teff/mem in grafted islets is more similar to Vb usage in the
endogenous islets than that in the spleen, PLN and RLN.
Discussion
The TCR Vb repertoire of islet-infiltrating T cells has been
investigated mostly by RT-PCR from bulk RNA isolated from the
islets or via flow cytometric-sorted MHC multimer-binding T cells
[20,21,32,42,46–56]. Studies using the former approach typically
have not distinguished between naı̈ve and eff/mem T cells. The
use of MHC multimer-sorted T cells is also limited since
information is obtained for clonotypes specific only for a given
peptide epitope. To overcome these limitations, a novel multi-
parameter flow cytometry approach was employed to characterize
the TCR Vb repertoire of CD4+ and CD8+ T cells involved in
autoimmune destruction of islet grafts in individual NOD
recipients. The approach permits analyses of general shifts in
TCR usage in a tissue-specific manner while taking in consider-
ation the activation status of the T cells. Exploiting this strategy, 3
key observations were made. First, naı̈ve CD4+ and CD8+ T cells
make up a significant frequency of islet graft-infiltrating T cells,
which express a TCR repertoire analogous to naı̈ve T cells in
peripheral lymphoid organs and endogenous islets. Second, TCR
Vb usage by islet graft-infiltrating Teff/mem is restricted, with the
TCR repertoire of CD8+ versus CD4+ Teff/mem exhibiting
distinct characteristics. Third, the TCR Vb repertoire is similar for
CD8+ and CD4+ Teff/mem infiltrating grafted and endogenous
islets of a given NOD recipient.
Our group has previously reported a high frequency of naı̈ve T
cells infiltrating the pancreas of NOD mice [57]. A similarly high
percentage of naı̈ve T cells was also detected in grafted islets.
Currently there is controversy regarding the need for antigen
stimulation of b cell-specific T cells to traffick into the islets
[47,58–60]. The fact that naı̈ve CD4+ and CD8+ T cells are found
Figure 4. The frequency of H2Kd-IGRP206–214 binding by TCR
Vb8.1/2-expressing CD8+ Teff/mem in grafted and endogenous
islets in NOD recipients. The frequency of islet graft and pancreas-
infiltrating TCR Vb8.1/2 CD8+ T cells binding H2Kd-IGRP206–214 tetramer
was determined for an individual NOD recipient (n = 6).
doi:10.1371/journal.pone.0052054.g004
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Figure 5. Analyses of TCR Vb chain usage by CD4+ Teff/mem in islet graft NOD recipients. (A) Percentage of CD4+ Teff/mem expressing
specific TCR Vb chains in spleen, PLN, RLN, pancreas, and islet graft of individual NOD mice (n = 13). (B) TCR Vb chain usage by CD4+ Teff/mem was
normalized by subtracting the frequency of the corresponding TCR Vb chain expressed by splenic, naı̈ve CD4+ T cells for a given NOD recipient.
***p,0.001, *p,0.05; One way ANOVA with Dunn’s post-test.
doi:10.1371/journal.pone.0052054.g005
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at a relatively high frequency argues against antigen-specificity/
stimulation playing an essential role for T cell trafficking into
grafted and endogenous islets. This scenario is further supported
by our observation that TCR Vb usage by naı̈ve T cells in the islet
graft and pancreas is identical to the spleen, PLN and RLN
(Figure 2), and lacks the restriction seen by antigen-stimulated
Teff/mem. Ongoing inflammation and production of chemokines
for example, likely provide signals that promote trafficking of naı̈ve
T cells into the respective tissues. Indeed, naı̈ve T cells are readily
detected in islet grafts at day 10 post-implantation but comprise
only a small percentage of T cells 5 days after transplantation
(unpublished results; R.D., A.G, R.T.). Our findings also un-
derscore the need to define the activational status of T cells in
order to accurately determine potential shifts in TCR repertoire.
For example, a predominant pool of naı̈ve T cells may obscure
subtle but significant changes in TCR usage by disease-relevant
Teff/mem.
We have reported earlier that islet graft-infiltrating IGRP206–
214-specific CD8
+ T cells exhibit a skewed repertoire consisting of
1 to 3 clones based on TCR Vb CDR3 sequences [32]. Analyses
of TCR Vb usage carried out in the current study indicate that
a highly restricted TCR repertoire is in fact a general property of
Table 3. Frequency of TCR Vb chains expressed by islet graft infiltrating CD4+ Teff/mem.
Vb Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 Mouse 7 Mouse 8 Mouse 9 Mouse 10Mouse 11Mouse 12Mouse 13
2 5.7 7.5 5.6 15.3 7.4 8.9 5.5 5.6 4.8 8.2 9.8 5.3 6.5
3 0.2 0.3 0.5 0.1 0.6 0.2 0.6 0.5 0.4 0.4 0.5 0.4 0.5
4 4.1 12.3 6.0 2.9 6.0 4.5 4.1 5.3 5.0 5.7 7.3 6.5 5.9
5.1/2 0.3 0.5 0.6 0.2 0.2 0.2 0.3 0.2 0.8 0.6 1.0 0.7 0.6
6 7.3 7.3 7.3 9.8 6.1 8.2 16.2 11.9 8.1 7.6 7.8 10.2 8.9
7 1.0 1.6 1.7 1.4 2.5 1.6 1.7 9.0 1.6 1.8 3.1 1.6 1.9
8.1/2 10.8 18.3 14.2 12.3 13.5 13.2 14.5 11.3 16.8 22.2 19.4 14.0 21.1
8.3 5.3 5.9 7.3 5.1 6.7 12.9 5.8 4.7 7.1 8.5 9.8 14.8 8.0
9 0.5 4.2 0.8 0.5 1.5 0.8 5.2 0.4 1.1 0.7 0.8 0.8 0.7
10 4.7 2.5 3.5 0.9 1.9 2.3 1.5 1.7 1.9 3.2 1.9 2.5 2.7
11 4.2 4.4 5.4 17.5 6.2 6.5 7.3 5.7 9.7 6.3 6.8 4.0 6.8
12 30.2 11.3 19.2 12.6 7.9 18.0 9.1 18.2 18.6 5.5 7.9 13.4 7.6
13 3.3 2.2 2.4 2.7 2.3 1.9 2.5 1.8 1.4 2.4 2.3 1.5 2.2
14 3.6 4.3 5.9 5.9 4.5 3.5 5.0 3.2 6.0 6.0 6.6 4.1 5.9
Nonreactive 5.7 7.5 5.6 15.3 7.4 8.9 5.5 5.6 4.8 8.2 9.8 5.3 6.5
doi:10.1371/journal.pone.0052054.t003
Table 4. Frequency of TCR Vb chains expressed by pancreas infiltrating CD4+ Teff/mem.
Vb Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 Mouse 7 Mouse 8 Mouse 9 Mouse 10Mouse 11Mouse 12Mouse 13
2 7.7 3.8 5.7 6.7 7.8 9.6 4.5 4.5 5.5 6.1 9.9 5.4 4.7
3 0.6 0.1 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.6 0.5 0.5 0.6
4 3.6 8.7 6.3 6.3 6.2 5.8 5.3 5.5 5.8 5.1 5.6 5.6 5.8
5.1/2 0.3 0.5 0.4 0.7 0.4 0.4 0.4 0.2 1.3 1.3 0.4 0.9 1.0
6 9.1 7.8 7.5 8.4 6.7 7.4 10.0 9.8 8.9 7.1 6.4 10.1 8.4
7 1.3 1.6 1.7 2.5 3.5 2.1 2.2 3.7 1.7 1.3 1.9 2.5 2.5
8.1/2 15.0 20.8 18.5 21.5 14.0 18.4 17.8 15.2 20.1 30.9 22.6 17.9 22.0
8.3 7.6 7.2 8.5 8.3 7.6 9.7 7.3 6.0 7.5 6.0 7.4 9.3 7.6
9 0.6 1.4 1.1 1.3 1.4 1.0 6.5 0.6 1.3 1.5 0.5 0.4 0.4
10 2.6 3.4 3.4 2.2 2.3 2.8 2.5 2.1 2.6 1.7 1.5 1.8 2.9
11 5.5 5.5 5.2 6.2 7.6 6.9 6.8 7.6 8.2 5.0 5.3 5.3 5.8
12 17.1 8.5 12.2 6.2 6.8 8.9 5.4 8.9 12.6 6.2 11.0 7.6 5.9
13 1.0 1.8 2.5 2.3 2.5 2.5 2.3 2.3 1.6 1.3 1.8 0.6 1.6
14 4.9 6.2 6.1 3.8 4.5 4.8 6.0 4.2 4.7 5.7 8.2 4.9 5.6
Nonreactive 7.7 3.8 5.7 6.7 7.8 9.6 4.5 4.5 5.5 6.1 9.9 5.4 4.7
The frequency of Ki67-staining CD4+ and CD8+ Teff/mem was determined in the spleen, islet graft and pancreas of individual NOD recipients.
***p,0.001,
**p,0.01; Student’s t test.
doi:10.1371/journal.pone.0052054.t004
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CD8+ Teff/mem infiltrating an islet graft and the pancreas. Islet
graft-infiltrating CD8+ Teff/mem expressed 1 to 4 prevalent TCR
Vb chains in a given NOD recipient (Figure 3; Table 1), which in
turn was demonstrated by reduced entropy relative to CD8+ Teff/
mem found in the spleen, PLN and RLN of recipient NOD mice
(Figure 7A). Furthermore, TCR Vb usage by islet graft-infiltrating
CD8+ Teff/mem varied markedly among NOD recipients
(Figure 3B,D; Table 1), again consistent with our earlier
observations made for IGRP206–214-specific CD8
+ T cells [32].
Noteworthy is that up to 65% of islet graft-infiltrating CD8+ T
cells expressing TCR Vb8.1/2 were IGRP206–214-specific
(Figure 4). Whether the different TCR Vb chains used by CD8+
Teff/mem among individual NOD recipients is due to recognition
of the same autoantigen by distinct clones, and/or multiple
autoantigens and/or epitopes remains to be determined.
Analogous to CD8+ Teff/mem, islet graft-infiltrating CD4+
Teff/mem were characterized by expression of a limited number
of prevalent TCR Vb chains (Figure 4; Table 3). Nevertheless,
TCR Vb usage by CD4+ Teff/mem exhibited characteristics
distinct from CD8+ Teff/mem. The most striking difference was
the increased usage of TCR Vb12 by islet graft-infiltrating CD4+
Teff/mem in the majority (12/13) of NOD recipients (Figure 5;
Table 3). Skewed TCR Vb12 usage by CD4+ T cells in the
pancreas of prediabetic NOD mice has previously been reported
[19,49,56,61]. In view of the high frequency of H2Kd-IGRP206–214
binding among TCR Vb8.1/2-expressing CD8+ Teff/mem
(Figure 4), it is tempting to speculate that TCR Vb12-expressing
CD4+ Teff/mem also represent a set of clones targeting
a particular b cell autoantigen [61]. Interestingly, TCR Vb12
expression appears to be primarily associated with pathogenic
CD4+ Teff/mem since islet graft and pancreas-infiltrating
Foxp3+CD4+ T cells do not exhibit the same increase of TCR
Vb12 usage within and among the individual NOD recipients
(unpublished results; R.D., A.G., and R.T.). TCR Vb usage by
islet graft (and pancreas)-infiltrating CD4+ Teff/mem also differed
in terms of the extent of overall diversity compared to CD8+ Teff/
mem. Despite increased usage of certain TCR Vb chains (e.g.
Vb12), islet graft-infiltrating CD4+ Teff/mem also expressed other
Vb chains at frequencies similar to naı̈ve CD4+ T cells residing in
the spleen (Figures 2, 5; Table 3). For instance, in the islet graft of
mouse #1 in which TCR Vb12 (30.2%), and Vb8.1/2 (10.8%)
were markedly increased, other prevalent TCR Vb chains were
used by CD4+ Teff/mem including Vb2 (5.7%), Vb4 (4.1%), Vb6
(7.3%), Vb8.3 (5.3%), Vb10 (4.7%), and Vb11 (4.2%) (Table 3).
Consequently, TCR Vb diversity within islet graft and pancreas-
infiltrating CD4+ versus CD8+ Teff/mem was increased
(Figures 3A, 5A), which was evident by no significant change in
Shannon entropy for CD4+ Teff/mem between tissues (Figure 7A).
The more diverse TCR Vb repertoire may indicate a broader
range of b cell autoantigens targeted in the islet grafts (and
pancreas) by CD4+ versus CD8+ Teff/mem.
Immunodominance of particular TCR Vb-expressing Teff/
mem is expected to be attributed to clonal expansion within the
islet grafts. Indeed, evidence indicates that increased TCR Vb
chain usage is associated with elevated proliferation of Teff/mem
residing in the islet graft (and pancreas). For instance, TCR Vb12-
expressing CD4+ Teff/mem found in the grafted and endogenous
islets displayed increased proliferation relative to the PLN and
RLN (and spleen) (Figure 6B), consistent with antigen-driven
expansion. In addition, ,70% of islet graft-infiltrating CD8+ Teff/
mem were proliferating based on Ki67-staining (Figure S1).
Interestingly, the frequency of proliferating CD4+ Teff/mem was
,2-fold less (Figure S1), which may partly explain the greater
skewing of TCR usage seen by CD8+ versus CD4+ Teff/mem in
the islet grafts (Figures 3A, 5A). In contrast, a diverse TCR
repertoire was associated with the nonproliferating, naı̈ve CD8+
and CD4+ T cells found in the islet graft and pancreas.
Another key observation made in this study is that the TCR Vb
repertoire of islet graft-infiltrating CD4+ and CD8+ Teff/mem was
more similar to the repertoire of Teff/mem residing in the
pancreas than that detected in the PLN, RLN, and spleen
(Figure 7B). In addition, similarities in TCR repertoires between
the 2 sites was evident by equivalent frequencies of IGRP206–214-
specific CD8+ Teff/mem among TCR Vb8.1/2 expressing cells in
grafted and endogenous islets (Figure 4). Increased frequencies of
proliferating TCR Vb12-expressing CD4+ Teff/mem were also
observed in both the grafted and endogenous islets of NOD
recipients (Figure 6B). This data supports a scenario in which
b cell-specific T cells mediating recurrent autoimmunity are
recruited from a pool of CD4+ and CD8+ Teff/mem involved in
Figure 6. Tissue distribution and proliferation of TCR Vb12-expressing CD4+ Teff/mem in NOD islet graft recipients. (A) Comparison
among tissues of the change in frequency of TCR Vb12-expressing CD4+ Teff/mem normalized by subtracting the percentage of TCR Vb12-expressing
splenic, naı̈ve CD4+ T cells for a given NOD recipient (n = 13). (B) The tissue distribution of TCR Vb12-expressing CD4+ Teff/mem staining for Ki67.
***p,0.001, **p,0.01, *p,0.05; Kruskal-Wallis test with two-sided Dunn’s post-test.
doi:10.1371/journal.pone.0052054.g006
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endogenous islet destruction, rather than from naı̈ve b cell-specific
clonotypes found in the periphery. The rapid kinetics of syngeneic
islet graft rejection, generally seen within 10–14 days post-
implantation, is consistent with the recruitment of established
b cell-specific Teff/mem. Additional studies are needed to directly
define the specificity of Teff/mem residing in the grafted and
endogenous islets to confirm our model.
In conclusion, our findings demonstrate that autoreactive Teff/
mem driving islet graft rejection express a restricted TCR
repertoire resembling that of Teff/mem involved in the de-
struction of endogenous islets. Notably, the nature of the TCR
repertoire regarding TCR Vb usage and the extent of diversity
differ between CD4+ and CD8+ Teff/mem infiltrating the islet
grafts. These findings provide new insight into the dynamics and
scope of the autoimmune TCR Vbrepertoire of CD4+ and CD8+
T cells, which may aid in the development of biomarkers and
more effective immunotherapies to monitor and block islet graft
rejection. Indeed, it is noteworthy that a recent study has shown
that treatment with an anti-TCR Vb13 antibody effectively
Figure 7. Tissue-specific TCR Vb chain diversity and distribution for CD4+ and CD8+ Teff/mem in NOD islet graft recipients. The
diversity (A) and distribution (B) of Vb chain usage by tissue-specific CD4+ and CD8+ Teff/mem in NOD islet graft recipients (n = 13) was determined
by Shannon entropy and Kullback-Leibler divergence, respectively. For the latter, the X axis represents comparisons of the respective tissues to the
islet graft of a given NOD recipient. *p,0.05; Kruskal-Wallis test with two-sided Dunn’s post-test.
doi:10.1371/journal.pone.0052054.g007
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NOD/LtJ and NOD.CB17.Prkdcscid/J (NOD.scid) mice were
bred and housed under pathogen-free conditions in an American
Association for Laboratory-accredited animal facility. NOD mice
were considered to be diabetic after 2 successive days of
$250 mg/dl blood glucose as measured by a Freestyle Lite blood
glucose monitor and strips (Abbott Diabetes Care Inc.). All
procedures were reviewed and approved by the University of
North Carolina Institutional Animal Care and Use Committee.
Islet Transplantation
Diabetic NOD female mice received 5 units of insulin daily
prior to transplantation. Five hundred syngeneic (NOD.scid) islets
were transplanted under the renal capsule of the left kidney. Blood
glucose values were monitored daily post-transplantation.
Flow Cytometry
Spleen, PLN, RLN, and pancreas single-cell suspensions were
prepared by grinding tissue between frosted slides in RPMI
complete containing 100 nM Dasatinib, which not only inhibits
downregulation of the TCR but it also increases TCR and co-
receptor surface expression allowing for better staining [62]. When
required, red cells were lysed with RBC lysis buffer. Islet grafts
were excised from the kidney and gently ground to release
infiltrating cells under the capsule and minimize kidney cell
contamination. Cells were washed with FACS buffer (PBS plus
0.5% BSA), filtered and blocked with aCD16/32 (2.4G2). Cells
were always kept in media containing 100 nM Dasatinib. Samples
were then split into three wells and stained. Thy1.1+ spleen cells
(16106) were added to wells containing cells from grafts and PLN/
RLN prior to addition of antibodies as a staining internal control.
Cells were stained with antibodies specific for CD90.2 (53–2.1),
CD8 (53–6.7), CD44 (IM7), CD62L (MEL-14) (BD Biosciences),
Thy1.1 (OX-7) (BioLegend), CD4+ (RM4-5) (Invitrogen) and three
different anti-TCR Vb panels. Panel A: aTCR Vb2-biotin
(B20.6), aTCR Vb3-PE (KJ25), aTCR Vb4-biotin (KT4), aTCR
Vb4-FITC, aTCR Vb6-biotin (RRA-7), aTCR Vb6-PE and
aTCR Vb9-FITC (MR10-2); Panel B: aTCR Vb5.1/2-biotin
(MR9-4), aTCR Vb7-PE (TR310), aTCR Vb8.1/2-FITC (MR5-
2), aTCR Vb 8.1/2-biotin and aTCR Vb8.3-FITC (1B3.3);
Panel C: aTCR Vb10[b]-FITC (B21.5), aTCR Vb 10[b]-PE,
aTCR Vb11-PE (RR3-15), aTCR Vb11-biotin, aTCR Vb12-
biotin (MR11-1), aTCR Vb13-PE (MR12-4) (Biolegend) and
aTCR Vb14-FITC (14–2). All aTCR Vb antibodies were
purchased from BD Biosciences unless noted. Binding of biotin-
labeled antibodies was revealed by streptavidin Alexa 594
(Invitrogen). Cells were washed twice with PBS and stained with
LIVE/DEADH Fixable Blue Dead Cell Stain Kit (Invitrogen) to
exclude dead cells. To stain for FoxP3 (FJK-16s) or Ki67 (B56)
samples were washed, fixed and permeabilized with eBiosciences
Fix/Perm kit following manufacturer’s indications. For tetramer
analysis, H2Kd-IGRP206–214 tetramers were prepared as pre-
viously described [32]. Cells were first stained with H2Kd-
IGRP206–214 for 40 minutes at room temperature, and then
placed on ice and incubated for 20 minutes with 100 mL of a 2X
cocktail of antibodies specific for T cell markers and TCR Vb
chains. Data was acquired at the University of North Carolina
Flow Cytometry Facility using a 6 laser (355 nm, 405 nm,
488 nm, 532 nm, 592 nm and 640 nm), 18 parameter LSRII
Special Order Research Product flow cytometer (BD Biosciences).
Analysis was performed with FlowJo software (Tree Star Inc.).
Diversity and Distribution Analyses
Shannon entropy was used as an index of TCR Vb usage
diversity. As described by Vincent et al [42], the entropy of a Vb
usage distribution is determined by two parameters: 1) the number
of different Vb chains that are expressed, and 2) the relative
frequency of each individual Vb chain. Entropy is greatest when
there are many different Vbs and when there are few Vb chains
that are highly represented in the population (i.e. few ‘‘dominant’’
families). If S is the total number of unique Vb chains in the pool,
and pi is the proportion of the pool represented by Vb i, the





The Kullback-Leibler34 divergence was used as an index of







where pi is the proportion of the pool represented by Vb i in the
first sample and qi is the proportion of that Vb in the second
sample.
Supporting Information
Figure S1 Increased proliferation of islet graft-infiltrating Teff/
mem in individual NOD recipients. The frequency of Ki67-
staining CD4+ and CD8+ Teff/mem was determined in the spleen,
islet graft and pancreas of individual NOD recipients. ***p,0.001,
**p,0.01; Student’s t test.
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